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Introduction
Meta-iodobenzylguanidine (MIBG) is a physiological analogue of norepinephrine (NE) that is actively transported into NE granules of sympathetic nerve terminals by the norepinephrine transporter (NET) [1, 2] . 123 I-MIBG is a radiolabeled version used to evaluate myocardial sympathetic nerve dysfunction in heart disease and to diagnose ischemic heart disease, cardiomyopathy, and heart failure.
Patients with Parkinson's disease show sympathetic nerve dysfunction in both the central and peripheral nervous systems [3] [4] [5] , which is reflected by a reduced cardiac uptake of 123 
I-MIBG. This finding in patients with
Parkinson's disease has attracted recent attention, with the reduction detectable before other autonomic disturbances and clinical features become evident including bradykinesia, resting tremor, rigidity, and response to levodopa. Thus, cardiac sympathetic nerve dysfunction might be a major pathology in Parkinson's disease, and 123 I-MIBG uptake is used increasingly in clinical examinations of patients with the disease [6] [7] [8] [9] [10] . However, changes in NE turnover observed in hearts with reduced 123 I-MIBG uptake remain unresolved, particularly as 123 I-MIBG has been associated with neuropathological findings in postmortem human heart [11] [12] [13] . Clarifying these changes in the hearts of patients with Parkinson disease might therefore help to elucidate the pathology of sympathetic nerve dysfunction.
The activity of the neurotoxic chemical agent 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine (MPTP) involves several steps. First, MPTP readily enters the brain and is converted, possibly in the glia, by monoamine oxidase B (MAO-B) to MPP+, which is most likely the toxic agent. The second step is the fairly selective uptake of MPP+ by dopaminergic terminals in the striatum via a monoamine transporter and subsequent intraterminal vesicular storage [14, 15] . MPTP produces symptoms resembling those of Parkinson's disease in humans and monkeys [16, 17] , and induces an almost complete, permanent, and selective degeneration of nigrostriatal dopaminergic neurons in a specific strain of mice [18, 19] .
Several studies have demonstrated reduced cardiac NE concentrations in mice treated with MPTP [20] [21] [22] [23] . Furthermore, pretreatment of mice with MPTP significantly reduces cardiac 125 I-MIBG uptake [24] [25] [26] [27] , similar to the effects observed in patients with Parkinson's disease.
Investigating the mechanism of reduced cardiac 123 I-MIBG uptake and NE turnover using an MPTP-induced mouse model of Parkinson's disease may help clarify the mechanism of sympathetic nerve dysfunction in human patients. However, previous preclinical mice studies were designed using a one-point, acute-phase analysis after MPTP administration [24] [25] [26] [27] . A multipoint analysis with a long-term observation period is necessary to investigate chronic neurodegenerative diseases like Parkinsonism.
The present experimental study investigated the long-term changes in cardiac 125 I-MIBG uptake and NE turnover by multipoint analysis in an MPTP-induced mouse model of Parkinson's disease.
Materials and methods
All experimental animal protocols were pre-approved by the Animal The protein concentrations were measured using the method described by
Lowry [30] . Binding assays were performed as described previously, with minor modifications [28, 29] Brandel, Gaithersburg, MD). Finally, each filter was rinsed three times with 5 ml of ice-cold 50-mM Tris-HCl buffer (pH 7.4). The radioactivity on the filters was determined using a liquid scintillation counter (LSC-5300, Aloka, Tokyo, JAPAN). Nonspecific binding was defined using 100 μM nisoxetine.
The B max was calculated from the specific binding values using Scatchard analyses. The B max was calculated in three independent experiments. The brain was placed in ice-cold physiological saline and allowed to cool for 1 min. A 1-mm slice passing through the striatum was transferred to a thin metal plate and placed on dry ice. After freezing, samples from the striatum (2 mm in diameter) were punched out. Pooled samples were assayed for DA concentration, and the measurement repeated 3 times in the same manner as for the heart.
Statistical analysis
All data were expressed as mean ± SD. All results were analyzed using a one-factor analysis of variance with the Bonferroni/Dunn correction for intergroup comparisons. The adjusted P values were calculated as the raw P value x (the number of groups − 1). An adjusted P value < 0.05 was considered statistically significant.
Results

Striatum DA concentration
The striatum DA concentrations were 49. No significant differences in cardiac TYR concentrations were observed among the groups (Figure 4 ).
Cardiac DA concentration
The cardiac DA concentrations were 2.3 ± 0.8 (x 10 4 pg/wet g) in group A, 1.5 ± 0.4 in group B, 1.8 ± 0.6 in group C, 1.8 ± 1.1 in group D, 1.9 ± 0.4 in group E, and 1.7 ± 0.7 in group F. The mean cardiac DA concentration in group B was slightly lower than that in group A, but the difference was not significant ( Figure 5 ).
Cardiac NE concentration
The cardiac NE concentrations were 6.8 ± 0.6 (x 10 5 pg/wet g)in group A, 2.2 ± 0.5 in group B, 4.9 ± 0.6 in group C, 5.9 ± 1.1 in group D, 6.5 ± 0.7 in group E, and 5.0 ± 1.2 in group F. The cardiac NE concentrations of groups B, C, and F were significantly lower than that of group A (P<0.001, for all comparisons), while those of groups C, D, E, and F were significantly higher than that of group B (P<0.001, for all comparisons), and those of groups D and E were significantly higher than that of group C (P<0.05, <0.001, respectively). The cardiac NE concentration of group F was significantly lower than that of group E (P<0.001). Thus, group A had an extremely high mean cardiac NE concentration and group B values were extremely low, while groups B, C, D, and E had gradually increasing concentrations ( Figure   6 ).
NE plasma concentration
The NE plasma concentrations were 5.0 ± 2.0 (x 10 3 pg/wet g) in group A, 2.3 ± 1.5 in group B, 5.1 ± 2.1 in group C, 4.3 ± 2.3 in group D, 3.3 ± 1.8 in group E, and 4.0 ± 3.5 in group F. The NE plasma concentration of group B was significantly lower than that of group A (P<0.05), while that of group C was significantly higher than that of group B (P<0.01) (Figure 7 ).
Discussion
The C57BL6 mouse has been used in many studies to investigate various aspects of Parkinson's disease [18] [19] [20] [21] [22] [23] . This mouse is highly sensitive to MPTP, which induces dose-dependent neurotoxic effects [31] [32] [33] [34] . This study used the modified protocol of Marien et al. [34] , in which 40 mg/kg of [13, 35, 36] . However, the difference between the cardiac DA and NE concentration patterns here was more marked than that between the TYR and DA concentrations. In addition, the mean cardiac NE concentration in group B was reduced to 33% of that in group A. According to the process of NE metabolism described by Eisenhofer et al. [37] , most of the NE released from vesicles at the sympathetic nerve terminal is taken up again by sympathetic nerves. The axoplasmic NE is either sequestered into vesicles or metabolized to dihydroxyphenylglycol in the normal human heart at rest. Because axoplasmic NE represents 90% of the NE that leaks from vesicles and only 10% of the NE that is released by sympathetic nerves and then taken up again by NET, NE synthesis is probably already severely damaged on day 1 after MPTP administration. However, these previous data represented the situation at rest, and the current study did not recapitulate the same circumstance. Thus, it added no data about the ratio of NE that is released and taken up in cardiac sympathetic nerve terminals immediately after MPTP administration, nor can it speak to the degree of cardiac NE synthesis obstruction after MPTP administration. It is therefore difficult to explain the recovery in cardiac NE concentration and the reduction after long-term repeated MPTP administration based on only the cardiac NET density, which showed little change. The cardiac NE concentration is likely to be greatly influenced by the pathway of NE synthesis in sympathetic nerves, with cardiac NET contributing significantly to the cardiac NE concentration on day 1 after MPTP administration, then to a lesser degree thereafter and after long-term repeated MPTP administration.
The plasma concentration of NE decreases rapidly and then recovers after MPTP administration [38] . In support of this, the present results showed a reduced NE plasma concentration on day 1 and subsequent recovery over a period of 4 days. This pattern of temporary decrease in plasma NE might reflect an acute adrenal gland insufficiency caused by MPTP. The absence of significant difference among groups C, D, E, and F further suggested that the NE plasma concentration does not contribute to cardiac NE turnover after 7-21 days and after long-term repeated MPTP administration.
We clarified the long-term change of reduced cardiac 125 I-MIBG uptake and NE turnover using Parkinson's disease model mice in this study.
In the next step, we plan to identify the molecules that are crucial for the control of cardiac NE turnover in Parkinson's disease. Ligands that reflect the activity of the molecules could provide more detailed information of sympathetic nerve dysfunction and make a breakthrough in the treatment for the sympathetic nerve dysfunction of patients with Parkinson's disease.
The multipoint analyses of cardiac 125 I-MIBG uptake and NE turnover using the same time scale after MPTP administration clearly showed that cardiac 125 I-MIBG uptake and NET density are rapidly reduced after MPTP administration, followed by the gradual recovery of 125 I-MIBG uptake.
There was an even greater reduction of 125 I-MIBG after long-term repeated MPTP administration, coincident with NE synthesis in the mice heart.
Conclusion
Changes in cardiac 125 I-MIBG uptake and NE turnover are closely related in postganglionic cardiac sympathetic nerve terminals in the hearts of mice with MPTP-induced Parkinsonism. 
Figure legends
